



2019 DISCLOSURE OF INTEREST INFORMATION

# GINA BOARD OF DIRECTORS

Louis-Philippe Boulet MD - *Chair*

Eric D. Bateman, MD

Guy Brusselle, MD, PhD, FERS

Alvaro A. Cruz, MD

Mark FitzGerald, MD

Hiromasa Inoue, MD

Jerry A. Krishnan, MD, PhD

Mark L. Levy, MD

Jiangtao Lin, MD

Helen K. Reddel, MBBS, PhD

Arzu Yorgancioglu, MD

# GINA SCIENCE COMMITTEE

Helen K. Reddel, MBBS, PhD - *Chair*

Len Bacharier, MD

Eric D. Bateman, MD

Louis-Philippe Boulet MD

Chris Brightling MD

Guy Brusselle, MD, PhD, FERS

Dr. Roland Buhl

Liesbeth Duijts, MD

Mark FitzGerald, MD

Louise Fleming, MD

Hiromasa Inoue, MD

Jerry A. Krishnan, MD, PhD

Kevin Mortimer, MD

Paulo Pitrez, M.D., Ph.D.

Aziz Sheikh, MD

Dr Fanny Wai-san Ko

# GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST

January 1, 2019 - December 31, 2019

## Background

The Global Initiative for Asthma (GINA) program is a collaboration between the scientific community and the private sector. The major objectives are: (1) to increase awareness of asthma among health professionals, health authorities, and the general public; (2) improve diagnosis, management, and prevention; and (3) stimulate research. These objectives are being met through preparation of scientific reports on asthma, dissemination and adoption of recommendations in these reports, and promotion of international collaboration on asthma research.

The purpose of this document is to safeguard the interests of all GINA collaborators by an open disclosure of interests.

## GINA Structure

At present, the GINA program is conducted through a GINA Board of Directors that meets annually (usually in January), a Scientific Committee and a Dissemination Committee. Each Committee will have an active role in reviewing and recommending content for GINA documents and all members will be asked to complete this form.

## Annual Declaration of Interests

The following declarations are requested by GINA. Please complete the company name select in the corresponding box whether you have financial relationships (received grants, personal fees, shares, non-financial support, other). Please include all companies in the bio-medical arena, as well as telehealth/technology, and tobacco entities. This form will be posted on the GINA website after completion.

### Definitions:

1. **Grants:** refers to any grant paid to your organization.
2. **Personal Fees:** refers to honorarium, consultation fees, etc for lectures, advisory committees or consultancy services either intermittent or regular, from which a GINA member benefits personally. This includes ongoing attendance at advisory board meetings but would not normally include a situation where an individual is paid for a specific item or for attending or speaking at an occasional meeting.
3. **Shares:** refers to any shares in asthma-related commercial organizations, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GINA member or family members (spouse/children). The company is to be listed, not the number of shares.
4. **Non-Financial Support:** In-kind assistance.

The private sector should not in any way be involved in any aspect of developing documents, including collecting, reviewing or accessing the literature or determining the content. Once documents have been produced asthma-related commercial organizations can be involved in their dissemination and audit, including support for publications.



**DISCLOSURE OF INTEREST**  
**FOR THE PERIOD Jan 01, 2019 to Dec 31, 2019**

Name: Leonard B Bacharier, MD

Member of (choose one or more):

☐ GINA Board of Directors

☒ GINA Science Committee

☐ GINA Assembly

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
AstraZeneca	NO	Yes	No	No	Speaking fees, advisory board fees
Regeneron	No	Yes	No	No	Speaking fees, advisory board fees
Sanofi	No	Yes	No	No	Speaking fees, advisory board fees
GlaxoSmithKline	No	Yes	No	No	Speaking fees
DBV Technologies	No	Yes	No	No	DSMB
Novartis	No	Yes	No	No	Speaking fees, advisory board fees
AAAAI	No	Yes	No	No	Associate Editor, JACI
ACAAI	No	Yes	No	No	Development of Asthma Yardstick documents
CF Foundation	No	Yes	No	No	DSMB
American Board of Allergy and Immunology	No	Yes	No	No	Vice Chair

**TOBACCO INDUSTRY FUNDING**

X I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature Leonard B Bacharier MD

Date: 2/17/2020



**GLOBAL INITIATIVE FOR ASTHMA (GINA)  
DISCLOSURE OF INTEREST  
FOR THE PERIOD Jan 01, 2019 to Dec 31, 2019**

Name: **Eric D Bateman**

Member of (choose one or more):

- ☐ GINA Board of Directors  
☐ GINA Science Committee  
☐ GINA Assembly

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
AstraZeneca		X			Advisory board, lecture fees, consultancy
ALK		X			Advisory board, lecture fees, consultancy
Novartis		X			Advisory board, lecture fees, consultancy
Sanofi		X			Advisory board, lecture fees
Regeneron		X			Advisory board, lecture fees
Orion		X			Lecture fee
Menarini		X			Lecture fee
Medscape		X			Lecture fee

**TOBACCO INDUSTRY FUNDING**

**X** I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature

Date: March 3<sup>rd</sup>, 2020



**GLOBAL INITIATIVE FOR ASTHMA (GINA)  
DISCLOSURE OF INTEREST  
FOR THE PERIOD Jan 01, 2019 to Dec 31, 2019**

Name: Louis-Philippe Boulet

Member of (choose one or more):

☒ GINA Board of Directors

☒ GINA Science Committee

☐ GINA Assembly

Are there any relevant financial interests to disclose?

Name of Entity	Grant ?	Personal Fee?	Non- Financial Support?	Other ?	Nature of involvement:
AstraZeneca	X				Investigator
AstraZeneca		X to my group			Conferences and Advisory Board
Boston Scientific	X				Co-investigator
GlaxoSmithKline		X to my group			Conferences
Novartis		X to my group			Conferences
Novartis	X				Investigator
Sanofi	X				Investigator
GlaxoSmithKline	X				Investigator
Merck		X to my group			Conferences
Teva		X to my group			Conferences
AstraZeneca, GlaxoSmithKline, Novartis, Boehringer-Ingelheim, Merck		X to Universit y Chair			Independent production of educational material

**TOBACCO INDUSTRY FUNDING**

X I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature

Date: 2020-2-25



**GLOBAL INITIATIVE FOR ASTHMA (GINA)**  
**DISCLOSURE OF INTEREST**  
**FOR THE PERIOD Jan 01, 2019 to Dec 31, 2019**

Name: \_\_\_\_\_ Chris Brightling \_\_\_\_\_

Member of (choose one or more):

- ☐ GINA Board of Directors  
☒ GINA Science Committee  
☐ GINA Assembly

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
GlaxoSmithKline	X				Research grants paid to Institution
AstraZeneca/MedImmune	X	X			Research grants and consultancy paid to Institution
Novartis	X	X			Research grants and consultancy paid to Institution
Chiesi	X				Research grants paid to Institution
Boehringer-Ingelheim	X	X			Research grants and consultancy paid to Institution
Mologic	X	X			Research grants and consultancy paid to Institution
TEVA		X			Consultancy paid to Institution
4DPharma	X	X			Research grants and consultancy paid to Institution
Sterna		X			Consultancy paid to Institution
Gossamer	X	X			Research grants and consultancy paid to Institution
Merck	X				Research grant paid to Institution
Quench		X			Consultancy paid to Institution
Regeneron		X			Consultancy paid to Institution
Sanofi		X			Consultancy paid to Institution
Roche/Genentech	X				Consultancy paid to Institution

**TOBACCO INDUSTRY FUNDING**

☒ I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature \_\_\_\_\_

Date: \_\_\_\_\_ 7<sup>th</sup> February 2020 \_\_\_\_\_



**GLOBAL INITIATIVE FOR ASTHMA (GINA)**  
**DISCLOSURE OF INTEREST**  
**FOR THE PERIOD Jan 01, 2019 to Dec 31, 2019**

Name: Guy Brusselle \_\_\_\_\_

Member of (choose one or more):

☒ GINA Board of Directors

☒ GINA Science Committee

☐ GINA Assembly

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
Astra Zeneca		Yes			Speaker's Fee and Advisory Board
Boehringer-Ingelheim		Yes			Speaker's Fee and Advisory Board
Chiesi		Yes			Speaker's Fee and Advisory Board
GlaxoSmithKline		Yes			Speaker's Fee and Advisory Board
Novartis		Yes			Speaker's Fee and Advisory Board
Sanofi		Yes			Advisory Board
Teva		Yes			Speaker's Fee and Advisory Board

**TOBACCO INDUSTRY FUNDING**

x I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature Guy Brusselle \_\_\_\_\_

Date: 11/FEB/2020 \_\_\_\_\_

A handwritten signature in blue ink, appearing to read "Guy Brusselle", is written over a horizontal line.







**GLOBAL INITIATIVE FOR ASTHMA (GINA)  
DISCLOSURE OF INTEREST  
FOR THE PERIOD January 2020 to January 2021**

Name: Liesbeth Duijts

Member of (choose one or more):

☐ GINA Board of Directors

☒ GINA Science Committee

☐ GINA Assembly

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
European Union's Horizon 2020 research and innovation programme	x				Research Grants
European Respiratory Society Congress		x		x	Invited speaker, research meetings

**TOBACCO INDUSTRY FUNDING**

I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature:

A handwritten signature in purple ink, appearing to read "L. Duijts", is written over a light blue rectangular background.

Date: January 20<sup>th</sup>, 2020

**GLOBAL INITIATIVE FOR ASTHMA (GINA)**  
**DISCLOSURE OF INTEREST**  
**FOR THE PERIOD Jan 01, 2019 to Dec 31, 2019**



Name: Alvaro A. Cruz

Member of (choose one or more):

☒ GINA Board of Directors

☐ GINA Science Committee

☐ GINA Assembly

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
GSK - Global	X	X			Investigator initiated project and advisory boards
SANOFI	X	X			Remuneration for clinical trials, lectures and advisory board
AstraZeneca	X	X			Remuneration for clinical trials, lectures and advisory board
Boehringer Ingelheim		X			Remuneration for lectures and advisory board
Novartis		X			Remuneration for lectures
Chiesi			X		Remuneration for lectures and travel support
Eurofarma		X			Remuneration for lectures
Mylan		X			Remuneration for advisory board
Circassia		X			Remuneration for advisory board

**TOBACCO INDUSTRY FUNDING**

X I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature

Date: 10 Feb 2020

Name: Álvaro A. Cruz



**GLOBAL INITIATIVE FOR ASTHMA (GINA)  
DISCLOSURE OF INTEREST  
FOR THE PERIOD Jan 01, 2019 to Dec 31, 2019**

Name: JM FitzGerald

Member of (choose one or more):

☒ GINA Board of Directors

☒ GINA Science Committee

☐ GINA Assembly

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
A-Z	Yes	Yes	No	No	Member of advisory boards, speaker bureau, and research grants paid directly to UBC
GSK	Yes	Yes	No	No	Member of advisory boards, speaker bureau, and research grants paid directly to UBC
Novartis	Yes	Yes	No	No	Member of advisory boards, speaker bureau, and research grants paid directly to UBC
Teva	Yes	Yes	No	No	Member of advisory boards, speaker bureau, and research grants paid directly to UBC
Sanofi Regeneron	Yes	Yes	No	No	Member of advisory boards, speaker bureau, and research grants paid directly to UBC
Gossamer	Yes				Paid directly to UBC

**TOBACCO INDUSTRY FUNDING**

☐ I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature \_\_\_\_\_

Date: \_\_\_\_\_



**GLOBAL INITIATIVE FOR ASTHMA (GINA)  
DISCLOSURE OF INTEREST  
FOR THE PERIOD Jan 01, 2019 to Dec 31, 2019**

Name: \_\_\_\_\_ Dr Louise Fleming \_\_\_\_\_

Member of (choose one or more):  
GINA Science Committee

Are there any relevant financial interests to disclose? Yes

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
Novartis		Fee paid to institution			Educational lecture
Teva		Fee paid to institution			Educational lecture
Astra Zeneca		Fee paid to institution			Attendance at standalone advisory board
Respiri UK		Fee paid to institution			Attendance at standalone advisory board

**TOBACCO INDUSTRY FUNDING**

☒ I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature \_\_\_\_\_  \_\_\_\_\_

Date: \_\_\_\_\_ 14/02/2020 \_\_\_\_\_



**GLOBAL INITIATIVE FOR ASTHMA (GINA)  
DISCLOSURE OF INTEREST  
FOR THE PERIOD Jan 01, 2019 to Dec 31, 2019**

Name: Hiromasa Inoue, MD

Member of (choose one or more):

- ☒ GINA Board of Directors
- ☒ GINA Science Committee
- ☐ GINA Assembly

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
Boehringer-Ingelheim	X	X			
Kyorin Pharmaceutical	X	X			
Novartis Pharma	X	X			
Ono Pharmaceutical	X				
Merck Sharp & Dohme		X			
Teijin Pharma	X				
Taiho Pharmaceutical	X				
AstraZeneca		X			
Astellas		X			
GlaxoSmithKline		X			
Sanofi		X			
Ohtsuka		X			
Meiji Seika Pharma	X				

**TOBACCO INDUSTRY FUNDING**

☒ I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature Hiromasa Inoue

Date: February 18, 2020



**GLOBAL INITIATIVE FOR ASTHMA (GINA)  
DISCLOSURE OF INTEREST  
FOR THE PERIOD Jan 01, 2019 to Dec 31, 2019**

Name: \_\_\_\_\_Jerry A. Krishnan, MD, PhD\_\_\_\_\_

Member of (choose one or more):

- ☐ X GINA Board of Directors  
☐ X GINA Science Committee  
☐ GINA Assembly

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
U.S. National Institutes of Health; National Heart, Lung, and Blood Institute	X			X	PI or co-investigator, and travel reimbursement
American Lung Association	X				PI or co-investigator
U.S. Patient Centered Outcomes Research Institute				X (Research contract)	PI or co-investigator
ResMed & Inogen	X				PI or co-investigator on industry sponsored trial of portable oxygen concentrator
Critical Path Institute		X			Consultant for patient reported outcome measure
GINA				X	Travel reimbursement
Vanguard, Fidelity, TIAA-CREF				X	Retirement savings using mutual funds
American Thoracic Society				X	Travel reimbursement

**TOBACCO INDUSTRY FUNDING**

☐ X I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

*Jerry A. Krishnan*

Signature \_\_\_\_\_

Date: \_\_\_\_\_Feb 6 2020\_\_\_\_\_







**GLOBAL INITIATIVE FOR ASTHMA (GINA)  
DISCLOSURE OF INTEREST  
FOR THE PERIOD Jan 01, 2019 to Dec 31, 2019**

Name: \_\_\_\_\_ *Jiangtao Lin* \_\_\_\_\_

Member of (choose one or more):

- ☒ GINA Board of Directors  
☐ GINA Science Committee  
☐ GINA Assembly

Are there any relevant financial interests to disclose? No

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:

**TOBACCO INDUSTRY FUNDING**

☒ I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature \_\_\_\_\_ *Jiangtao Lin* \_\_\_\_\_

Date: \_\_\_\_\_ 7 Feb. 2020 \_\_\_\_\_



**GLOBAL INITIATIVE FOR ASTHMA (GINA)  
DISCLOSURE OF INTEREST  
FOR THE PERIOD 01/01/2019 to 31/12/2019**

Name: Kevin Mortimer

Member of (choose one or more):

☐ GINA Board of Directors


☒ GINA Science Committee

☐ GINA Assembly

Are there any relevant financial interests to disclose? Yes

Research grants:

- 2015 **Medical Research Council Doctoral Training Partnership.** Biagini G, Mortimer K (co-lead) and Diggle P. **£1.3m.** Translational and Quantitative Skills Doctoral Training Partnership in Global Health
- 2016 **Medical Research Council.** Mortimer K (PI). **£606,000.** Lung Health in Africa across the life course
- 2017 **National Institute for Health Research.** Squire SB, Mortimer K (co-I) et al. **£7m.** NIHR Global Health Research Unit on Lung Health and Tuberculosis in Africa at LSTM
- 2017 **Medical Research Council.** Biagini G, Mortimer K (co-lead) and Diggle P. **£257,469.** Liverpool School of Tropical Medicine and Lancaster University NPIF Studentships
- 2017 **Medical Research Council Skills Development Fellowship Programme.** Mortimer K (PI). **£580k.** Translational and Quantitative Skills Development Fellowships in Global Health
- 2017 **Medical Research Council NPIF Skills Development Fellowship.** Mortimer K (PI). **£286,000.** Translational and Quantitative NPIF Skills Development Fellowship in Global Health
- 2017 **Medical Research Council.** Allen S (PI), Mortimer K (co-I) et al. **£218,002.** Improving the survival, growth and developmental of low birth weight newborns through better nutrition
- 2018 **Medical Research Council.** Biagini G, Mortimer K (co-lead) and Diggle P. **£188,132.** Liverpool School of Tropical Medicine and Lancaster University NPIF Studentships
- 2018 **National Institute for Health Research.** Grigg J, Mortimer K (co-I) et al. **£2m.** NIHR Global Health Research Unit on improving asthma outcomes in African children at Barts and The London Queen Mary's School of Medicine and Dentistry
- 2018 **Wellcome Trust** Clinical PhD. Awarded to Sepedeh Saleh. Mortimer K (primary supervisor). **£455,000.** A new approach to air pollution in peri-urban Malawi.
- 2018 **The Academy of Medical Sciences.** Lesosky M (PI) and Mortimer K (co-I). **£92.6k.** Newton Advanced Fellowship: Biostatistical Methods for Bayesian Analysis of Multilevel Models of Lung Health in Africa.
- 2018 **Medical Research Council and Kenya National Research Fund Newton-Utafiti.** Mortimer K and Muhwa C (co-PIs). **£715k.** Non-communicable lung disease in Kenya: from burden and early life determinants to participatory inter-disciplinary solutions.
- 2018 **Medical Research Council Skills Development Fellowship Programme.** Mortimer K (PI). **£580k.** Translational and Quantitative Skills Development Fellowships in Global Health



x I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies



2



**GLOBAL INITIATIVE FOR ASTHMA (GINA)  
DISCLOSURE OF INTEREST  
FOR THE PERIOD January to December 2019**

Name: Paulo Márcio Pitrez

Member of (choose one or more):

- ☐ GINA Board of Directors  
☒ GINA Science Committee  
☐ GINA Assembly

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
Novartis		X			Ad Boards/Lectures
Boehringer Ingelheim		X			Ad Boards/Lectures
Sanofi		X			Ad Board
Circassia		X			Ad Board

**TOBACCO INDUSTRY FUNDING**

☒ I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature 

Date: 02/06/2020



**GLOBAL INITIATIVE FOR ASTHMA (GINA)  
DISCLOSURE OF INTEREST  
FOR THE PERIOD Jan 01, 2019 to Dec 31, 2019**

Name: Helen Reddel

Member of (choose one or more):

- ☒ GINA Board of Directors  
☒ GINA Science Committee  
☐ GINA Assembly

Are there any relevant financial interests to disclose? Yes

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
AstraZeneca	x	x			Advisory boards, steering committee, provision of independent medical education
GlaxoSmithKline	x	x			Provision of independent medical education; workshop; research registry
Novartis	x	x			Advisory board, research registry
Sanofi-Genzyme		x			Advisory board

**TOBACCO INDUSTRY FUNDING**

☒ I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature H. K. Reddel

Date: 9 February 2020



**GLOBAL INITIATIVE FOR ASTHMA (GINA)**  
**DISCLOSURE OF INTEREST**  
**FOR THE PERIOD Jan 01, 2019 to Dec 31, 2019**



Name: Ko Wai San Fanny

Member of (choose one or more):

- ☐ GINA Board of Directors  
☐ GINA Science Committee  
☐ GINA Assembly

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
Boehringer Ingelheim (HK) Ltd. through Hong Kong Thoracic Society: Support for attending the ATS 2019 conference				Attending conference	May 2019
GlaxoSmithKline through CHEST Delegation Hong Kong and Macau limited: Support for attending the ERS 2019 conference				Attending conference	September 2019

**TOBACCO INDUSTRY FUNDING**

I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature \_\_\_\_\_

Date: 7 Feb 2020



**GLOBAL INITIATIVE FOR ASTHMA (GINA)**  
**DISCLOSURE OF INTEREST**  
**FOR THE PERIOD Jan 01, 2019 to Dec 31, 2019**

Name: A Yorgancioglu

Member of (choose one or more):

- ☒ GINA Board of Directors  
☐ GINA Science Committee  
☐ GINA Assembly

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
Astra Zeneca	+	+			Grant to institution Advisory board, Invited speaker
Glaxo Smith Kline			+		Advisory board, Invited speaker
Novartis		+			Advisory board, Invited speaker
Sanofi		+			Advisory board, Invited speaker
Chiesi		+			Advisory board, Invited speaker
Abdi Ibrahim					Advisory board, Invited speaker
DEVA					Advisory board, Invited speaker
Global Alliance Against Respiratory Diseases (GARD/WHO)			+		Support for travel to meetings Chair
Turkish Thoracic Society			+		Support for travel to meetings

**TOBACCO INDUSTRY FUNDING**

☐ I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature \_\_\_\_\_

Date: \_\_\_\_\_